CTMedic wrote:
The lenzilumab trial started with ventilation as an exclusion criteria, so progression to ventilation or death is a very appropriate metric. Much more indicative than days to clinical improvement. Definitely a put up or shut up metric.

So "on ventilation" folks were always excluded? The change is, that folks in the trial who were not on ventilation, but advanced to ventilation, they will be excluded from data, correct?

That sure sounds like cheating, becaude,..... the HGEN drug did not prevent disease progression.